| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Bis(2-chloroethyl) phosphate has no therapeutic target. It is a metabolite and an environmental pollutant. It is a suspected carcinogen. It is formed in the body by the metabolism of TCEP. The parent compound, TCEP, is a neurotoxicant and has been shown to cause hippocampal brain lesions. The mechanism of toxicity may involve the disruption of lipid metabolism and cholinergic signaling. BCEP is not an enzyme inhibitor for therapeutic purposes.
|
|---|---|
| ln Vitro |
Bis(2-chloroethyl) phosphate is not a drug and has no direct in vitro biological activity as a therapeutic agent. It is a urinary metabolite of TCEP. The cytotoxicity (LC₅0) of BCEP was measured as 456 microM in primary mouse hepatocytes (PMH). This indicates it is moderately toxic. It is used as an analytical standard for the quantification of organophosphate flame retardants (OPFRs) in urine. It can also be used in in vitro metabolism studies to measure the activity of enzymes that hydrolyze TCEP. No specific IC₅0 values for receptor binding are available.
|
| ln Vivo |
In vivo, Bis(2-chloroethyl) phosphate is not used as a drug. It is a metabolite detected in the urine of humans and animals after exposure to TCEP. The median concentration in human urine is 0.68 ng/mL. It is a biomarker for assessing exposure to TCEP in occupational settings and the general population. Elevated levels of BCEP are associated with potential health risks, including hepatotoxicity and neurotoxicity. It is not a therapeutic agent.
|
| Enzyme Assay |
In vitro toxicity assay: Primary mouse hepatocytes (PMHs) are seeded in 96-well plates (1×10⁴ cells/well). After 24 h, the cells are treated with various concentrations of Bis(2-chloroethyl) phosphate (0-1000 uM) for 24 h. Cell viability is measured by the MTT assay or CCK-8 assay. The half-maximal lethal concentration (LC₅0) is calculated (456 uM). To measure metabolism, microsomal incubations with TCEP are performed, and BCEP formation is quantified by LC-MS/MS. For environmental analysis, water samples (1 L) are extracted with solid-phase extraction (SPE) (Oasis HLB cartridges) and analyzed by LC-MS/MS.
|
| Cell Assay |
Bis(2-chloroethyl) phosphate is not used in standard cell-based assays for drug discovery. For toxicity screening, HepG2 or HEK293 cells are seeded in 96-well plates (1×10⁴ cells/well) and treated with Bis(2-chloroethyl) phosphate (1-1000 uM) for 24-72 h. Cell viability is measured by MTT assay. The CC₅0 is expected to be > 200 uM, indicating moderate cytotoxicity. For metabolism studies, primary human hepatocytes are seeded in 6-well plates, treated with TCEP (10-100 uM), and the appearance of BCEP in the medium is measured by LC-MS/MS. The intrinsic clearance (Clint) is calculated.
|
| Animal Protocol |
For toxicokinetic studies, male Sprague-Dawley rats (200-250 g, n=6/group) are administered TCEP orally (10-100 mg/kg) in corn oil. Blood samples (0.5 mL) are collected by tail vein at 0, 0.5, 1, 2, 4, 6, 12, 24 h post-dose. Urine is collected in metabolic cages for 24 h. The concentration of Bis(2-chloroethyl) phosphate in plasma and urine is measured by LC-MS/MS. The half-life (t½) of TCEP in plasma is 2-4 h. The fraction of the dose excreted as BCEP is calculated (< 5%). The compound is not administered directly.
|
| ADME/Pharmacokinetics |
Bis(2-chloroethyl) phosphate (MW 222.99, Log P 0.5) is a polar, negatively charged molecule. It has low oral bioavailability due to its high water solubility. It is not metabolized further. It is rapidly excreted in the urine. The half-life of elimination in rats is 2-4 h. The compound is a major metabolite of TCEP. It is not intended for therapeutic use. For research use, it is stored as a solid at -20degC. It is soluble in water and DMSO.
|
| Toxicity/Toxicokinetics |
For Bis(2-chloroethyl) phosphate, hazard statements: H315 (Causes skin irritation), H319 (Causes serious eye irritation), H335 (May cause respiratory irritation). Signal word: Warning. Precautionary statements: P261 (Avoid breathing dust/fume/gas/mist/vapors/spray), P280 (Wear protective gloves/protective clothing/eye protection/face protection), P305+P351+P338 (IF IN EYES: Rinse cautiously with water for several minutes). The compound is an environmental pollutant and should be handled as a potential health hazard. Storage: at 2-8degC, sealed.
|
| References | |
| Additional Infomation |
Bis(2-chloroethyl) phosphate is a dialkyl phosphate ester.
Bis(2-chloroethyl) phosphate (BCEP; CAS# 3040-56-0) is a research-grade organophosphorus compound and a biomarker of exposure to the flame retardant TCEP. It is not an FDA-approved drug. It is used as a reference standard in environmental health studies for the quantification of TCEP metabolites in urine. For research use only, not for diagnostic or therapeutic applications. |
| Molecular Formula |
C4H9CL2O4P
|
|---|---|
| Molecular Weight |
222.99
|
| Exact Mass |
221.962
|
| CAS # |
3040-56-0
|
| Related CAS # |
Bis(2-chloroethyl) phosphate-d8; 1477495-02-5
|
| PubChem CID |
76438
|
| Appearance |
White to off-white oil
|
| Hydrogen Bond Donor Count |
1
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
11
|
| Complexity |
130
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(CCl)OP(=O)(O)OCCCl
|
| InChi Key |
PMGHIGLOERPWGC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C4H9Cl2O4P/c5-1-3-9-11(7,8)10-4-2-6/h1-4H2,(H,7,8)
|
| Chemical Name |
bis(2-chloroethyl) hydrogen phosphate
|
| Synonyms |
BCEP
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4845 mL | 22.4225 mL | 44.8451 mL | |
| 5 mM | 0.8969 mL | 4.4845 mL | 8.9690 mL | |
| 10 mM | 0.4485 mL | 2.2423 mL | 4.4845 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
